https://www.selleckchem.com/pr....oducts/Acadesine.htm
The 2018 wholesale acquisition cost (WAC) of osimertinib at $14,616 for a 30-day prescription was used. AEs3/4 were retrieved from the FLAURA trial. In the 1-year contract, the DSP of osimertinib was estimated at $14,627 (or +0.08% the 2018 WAC) for a 30-day prescription. In the 2-year contract, the DSP of osimertinib was estimated at $14,516 (or -0.68% the 2018 WAC) for a 30-day prescription. We demonstrated that pricing methods-based paybacks for safety issues leading to treatment discontinuation can be integrated into our proposed
پسندیدن
اظهار نظر
اشتراک گذاری
